Xilio Therapeutics Appoints Yariv Houvras as Chief Medical Officer

Xilio Therapeutics, Inc. (XLO) announced on September 28, 2026, the appointment of Yariv Houvras as Chief Medical Officer, effective immediately. Houvras will lead the clinical development of the company's tumor-activated immuno-oncology therapies. His appointment follows the departure of the prior CMO, though financial terms of the appointment were not disclosed. The company stated the transition supports ongoing clinical trials. XLO shares were unchanged in early trading following the announcement.